John Berriman

John Edward Berriman is the founder of Illumina Cambridge Ltd. Mr. Berriman is currently Non-Executive Chairman at Autifony Therapeutics Ltd. since 2011, Chairman at Depixus SAS since 2015, Non-Executive Director at Autolus Ltd., and Lead Independent Director at Autolus Therapeutics Plc since 2014.
Former roles include Non-Executive Chairman at ReNeuron Group Plc from 2015 to 2020, Executive Deputy Chairman at Oxxon Therapeutics, Inc. in 2006, Chairman at MyCartis NV, Deputy Chairman at Algeta ASA in 2008, Chairman at Nxera Pharma UK Ltd. from 2007 to 2015, Chairman at Confo Therapeutics NV from 2016 to 2023, Director at Celltech Group Plc in 1996, Director at Abingworth Management Ltd. from 1997 to 2004, Director at Abingworth LLP from 1997 to 2001, Non-Executive Director at Cytos Biotechnology AG in 2012, Director at Epigenomics AG in 2006, Director at Alnylam Pharmaceuticals, Inc. from 2003 to 2005, Director at Ablynx NV in 2005, Director at Chroma Therapeutics Ltd., Director at Varex Imaging Sweden AB, Director at Amgen Rockville, Inc. from 2006 to 2012, and Director at Micromet, Inc. Education includes undergraduate studies at the University of Cambridge and an MBA from London Business School.